| Bid | 1.02 |
| Market Cap | 23.82M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.76 |
| PE Ratio (ttm) | -1.36 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.09 |
| Volume | 75,614 |
| Avg. Volume (20D) | 295,386 |
| Open | 1.05 |
| Previous Close | 1.04 |
| Day's Range | 1.02 - 1.09 |
| 52-Week Range | 0.51 - 2.33 |
| Beta | undefined |
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC ...
Analyst Forecast
According to 1 analyst ratings, the average rating for NRSN stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
6 months ago · marketwatch.com
This cheap biotech offers investors a play on ALS if trial data continues to impressNeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.
